Publications:  Dr Maximilian Mossner

Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M et al.(2017). Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget vol. 8, (49) 84714-84728.

Khaled N, Mossner M, Fabarius A, Nowak D, Rinaldetti S, Spiess B, Seifarth W, Meggendorfer M et al. (2017). BCR-ABL independent gene mutations contributing to treatment resistance in chronic myeloid leukemia: A pilot study. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 147-147.

Jann JC, Mossner M, Nolte F, Boch T, Nowak V, Palme I, Oblaender J, Pressler J et al. (2017). Bone marrow derived mesenchymal stromal cells display transcriptomic changes during aging and onset of myelodysplasia. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 178-+.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Oblaender J, Pressler J et al. (2017). Clonal hierarchies and dynamic evolution in Myelodysplastic Syndromes (MDS) upon therapy. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 213-213.

Mossner M, Stoehr A, Jann JC, Nolte F, Nowak V, Oblaender J, Pressler J, Xanthopoulos C et al. (2017). Erythroferrone (ERFE) and Growth Differentiation Factor 15 (GDF15) are highly differentially overexpressed in CD71 positive Erythroprogenitor cells of patients with Myelodysplastic Syndromes and associated with survival. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 122-123.

Jann J-C, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I et al.(2017). Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. J Med Genet vol. 54, (9) 640-650.

Nolte F, Mossner M, Jann JC, Nowak D, Boch T, Müller NZ, Hofmann WK, Metzgeroth G(2017). Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects. European Journal of Haematology vol. 98, (3) 302-310.

Jann J-C, Mossner M, Nolte F, Boch T, Nowak V, Palme I, Obländer J, Pressler J et al. (2016). RNA Sequencing of Bone Marrow Derived Mesenchymal Stromal Cells (MSCs) of Healthy Young, Healthy Old and Patients with Myelodysplastic Syndrome (MDS) Reveals Transcriptomic Changes upon Aging of the Niche and Onset of MDS. Blood. vol. 128, 4300-4300.

Boch T, Luft T, Mossner M, Jann J-C, Nowak D, Folz C, Klemmer J, Brendel S et al. (2016). Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study. Blood. vol. 128, 228-228.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Oblaender J, Pressler J et al. (2016). Clonal hierarchies and dynamic evolution in Myelodysplastic Syndromes (MDS) upon therapy. ONCOLOGY RESEARCH AND TREATMENT. vol. 39, 213-213.

Boch T, Spiess B, Cornely OA, Vehreschild JJ, Rath PM, Steinmann J, Heinz WJ, Hahn J et al.(2016). Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clinical Microbiology and Infection vol. 22, (10) 862-868.

Mossner M, Stoehr A, Jann JC, Nolte F, Nowak V, Oblaender J, Pressler J, Xanthopoulos C et al. (2016). Erythroferrone (ERFE) and Growth Differentiation Factor 15 (GDF15) are highly differentially overexpressed in CD71 positive Erythroprogenitor cells of patients with Myelodysplastic Syndromes and associated with survival. ONCOLOGY RESEARCH AND TREATMENT. vol. 39, 122-123.

Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S, Mossner M, Schwartz S et al.(2016). Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL. J Hematol Oncol vol. 9, (1) 95-95.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J et al.(2016). Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood vol. 128, (9) 1246-1249.

Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D et al.(2016). Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: Results from a prospective multicenter study of the German MDS study group (GMDS). Leukemia vol. 30, (9) 1956-1959.

Boch T, Hofmann W-K, Kunz C, Fricke H, Luft T, Mossner M, Jann JC, Nowak D et al. (2016). Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study. Journal of Clinical Oncology. vol. 34, e18552-e18552.

Jann J-C, Nowak D, Nolte F, Fey S, Nowak V, Oblaender J, Pressler J, Fabarius AC et al. (2015). Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. Blood. vol. 126, 2891-2891.

Mossner M, Stoehr A, Jann J-C, Nolte F, Nowak V, Oblaender J, Pressler J, Xanthopoulos C et al. (2015). Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS). Blood. vol. 126, 2859-2859.

Mossner M, Spiess B, Jann J-C, Nowak V, Obländer J, Bader O, Hofmann W-K, Nowak D et al. (2015). Whole Genome Sequencing of Azole-Resistant Aspergillus Fumigatus Strains from Hematopoietic Stem Cell Recipients Identifies Candidate Molecular Targets Potentially Implicated in Novel Resistance Mediating Mechanisms - First Results. Blood. vol. 126, 4325-4325.

Jann JC, Mossner M, Nolte F, Fey S, Nowak V, Oblaender J, Pressler J, Fabarius A et al. (2015). Establishment of a novel "short tandem repeat" based multiplex-PCR assay for accurate del(5q) quantification using genomic DNA. Oncology Research and Treatment. vol. 38, 69-70.

Fransecky L, Neumann M, Heesch S, Schlee C, Tanchez OJ, Heller S, Schwartz S, Mochmann LH et al. (2015). Silencing of GATA3 defines a new stem cell subgroup of T-ALL. Oncology Research and Treatment. vol. 38, 88-+.

Mossner M, Stoehr A, Nolte F, Jann JC, Fey S, Nowak V, Oblaender J, Pressler J et al. (2015). The erythroid regulator Erythroferrone (ERFE) is differentially regulated in CD71+erythroprogenitor cells of patients with myelodysplastic syndromes (MDS) and is associated with prognosis. Oncology Research and Treatment. vol. 38, 68-68.

Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Fabarius A et al. (2015). 156 A NOVEL PCR-BASED ASSAY FOR TARGETED QUANTIFICATION OF DEL(5Q) IN MYELODYSPLASTIC SYNDROMES. Leukemia Research. vol. 39,

Mossner M, Stöhr A, Nolte F, Jann JC, Fey S, Nowak V, Obländer J, Pressler J et al. (2015). 227 CD71+ ERYTHROPROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES DISPLAY DISTURBED REGULATION OF ERYTHROPOIESIS STIMULATING ERYTHROFERRONE (ERFE) IN ASSOCIATION WITH DIFFERENTIAL PROGNOSTIC SIGNIFICANCE. Leukemia Research. vol. 39,

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J et al. (2015). 65 MYELODYSPLASTIC SYNDROMES ARE CHARACTERIZED BY RECURRENT PATTERNS IN PATIENT-INDIVIDUAL MUTATIONAL HIERARCHIES THAT ARE SUBJECT TO HIGHLY DYNAMIC SUBCLONAL EVOLUTION DURING THERAPY AND DISEASE PROGRESSION. Leukemia Research. vol. 39,

Medyouf H, Mossner M, Jann JC, Hofmann WK, Trumpp A, Nowak D (2015). Niche Dependency and Clonal Heterogeneity in Human Myelodysplastic Syndromes. ANNALS OF HEMATOLOGY. vol. 94, S38-S39.

Nowak D, Liem NLM, Mossner M, Klaumünzer M, Papa RA, Nowak V, Jann JC, Akagi T et al.(2015). Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Experimental Hematology vol. 43, (1) 32-43.

Mossner M, Jann JC, Launiger-Lörsch E, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A et al. (2014). Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. Blood. vol. 124, 1920-1920.

Jann J-C, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Fabarius A et al. (2014). Development of a DNA-Based Targeted Assay Suitable for Accurate Quantification of Chromosomal Deletions in Myelodysplastic Syndromes with Deletion (5q) and Other Clonal Diseases. Blood. vol. 124, 1925-1925.

Mossner M, Stöhr A, Nolte F, Jann J-C, Fey S, Nowak V, Obländer J, Pressler J et al. (2014). Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance. Blood. vol. 124, 4620-4620.

Lammer F, Klaumuenzer M, Mossner M, Jann JC, Hecht A, Nowak V, Fey S, Oblaender J et al. (2014). Next Generation RNA Sequencing of Acute Promyelocytic Leukemia (APL) Identifies Novel Long Non Coding RNAs Including New Variants of MIR181A1HG That Are Differentially Expressed during Myeloid Differentiation. Blood. vol. 124, 1031-1031.

Jann J-C, Nowak D, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J et al. (2014). Quantitative Analysis of Patient-Specific Lesions in Primary and Xenografted Myelodysplastic Syndromes Reveals Complex Hierarchies and Subclonal Diversity That Evolve during Disease Progression. Blood. vol. 124, 4604-4604.

launiger-Lörsch E, Luft T, Fey S, Obländer J, Brendel S, Pressler J, Jann J-C, Kunz C et al. (2014). The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study. Blood. vol. 124, 4669-4669.

Jann J-C, Nowak D, Nolte F, Fey S, Nowak V, Oblaender J, Pressler J, Muedder K et al. (2014). Analysis of patient-specific lesions reveals oligoclonal diversity, complexe hierarchies and dynamic evolution in primary and xenotransplanted bone marrow from patients with myelodysplastic syndromes. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 211-211.

Mossner M, Jann J-C, Launinger-Loersch E, Nowak D, Platzbecker U, Giagounidis A, Goetze K, Letsch A et al. (2014). Impact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 233-233.

Lauinger-Loersch E, Luft T, Fey S, Oblaender J, Brendel S, Jann J-C, Kunz C, Fricke H et al. (2014). Safety and efficacy of the fas ligand inhibitor APG101 in transfusion dependent patients with low risk MDS: interim results from a phase I study. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 235-235.

Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C et al. (2014). Xenografting human myelodysplastic syndromes reveals an essential role of the mesenchymal niche for disease expansion. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 43-43.

Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C et al.(2014). Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell vol. 14, (6) 824-837.

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D et al.(2014). Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). Journal of Cancer Research and Clinical Oncology vol. 140, (3) 411-417.

Platzbecker U, Sockel K, Schönefeldt C, Nowak D, Helas S, Röllig C, Mossner M, Jann JC et al.(2014). Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia. Haematologica vol. 99, (12) e247-e248.

Mossner M, Wilbertz A, Fey S, Obländer J, Nowak V, Vogler J, Nolte F, Bieber R et al. (2013). Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes. Blood. vol. 122, 1561-1561.

Medyoup H, Mossner M, Jann J-C, Nolte F, Eisen C, Lier A, Nowak V, Zens B et al. (2013). MDS-Derived Stromal Cells Exhibit Altered Gene Expression and Support The Engraftment Of lin-CD34+CD38- Disease-Initiating Stem Cells In a Xenograft Model Of Lower Risk MDS. Blood. vol. 122, 100-100.

Platzbecker U, Sockel K, Schönefeldt C, Nowak D, Helas S, Röllig C, Mossner M, Jann J-C et al. (2013). Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag. Blood. vol. 122, 4923-4923.

Jann J-C, Nowak D, Nolte F, Haferlach C, Staller M, Nowak V, Zens B, Müdder K et al. (2013). Next Generation Sequencing-Based Molecular Dissection Of Lineage-Specific Mutational Hierarchies In Oligoclonal Primary and Xenografted Myelodysplasia. Blood. vol. 122, 519-519.

Mossner M, Jann J-C, Lauinger-Lörsch E, Nowak D, Platzbecker U, Giagounidis A, Götze KS, Letsch A et al. (2013). TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. Blood. vol. 122, 2759-2759.

Kohlmann A, Martinelli G, Alikian M, Artusi V, Auber B, Belickova M, Bronzini I, Cazzaniga G et al. (2013). The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood. vol. 122, 743-743.

Nolte F, Kunz C, Fey S, Obländer J, Brendel S, Klaumünzer M, Mossner M, Jann J-C et al. (2013). The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS). Blood. vol. 122, 1562-1562.

Mossner M, Nowak D, Platzbecker U, Giagounidis A, Goetze K, Letsch A, Haase D, Shimeshan K et al. (2013). 454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial. ONKOLOGIE. vol. 36, 126-126.

Nolte F, Giehl M, Haass W, Nowak V, Schumann C, Nowak D, Mossner M, Popp HD et al.(2013). Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability. Annals of Hematology vol. 92, (10) 1325-1333.

Medyouf H, Mossner M, Nolte F, Jann J-C, Nowak V, Zens B, Muedder K, Klein C et al. (2013). Establishment of an in vivo model of low risk myelodysplastic syndrome (MDS) by co-transplantation of hematopoietic stem cells and bone marrow stromal cells from MDS patients into nod.cg-prkdc scid il2rgtm1wyl/szj (nsg) mice. ONKOLOGIE. vol. 36, 124-124.

Fey S, Oblaender J, Mossner M, Brendel S, Nowak D, Kunz C, Fricke H, Hofmann W-K et al. (2013). In vitro APG101 leads to an improved erythroid differentiation in primary CD34+cells from patients with myelodysplastic syndrome (MDS). ONKOLOGIE. vol. 36, 125-125.

Jann J-C, Mossner M, Klaumuenzer M, Hofmann W-K, Nowak D (2013). Spliceosome gene mutations are rare in acute promyelocytic leukemia (APL). ONKOLOGIE. vol. 36, 47-47.

Medyouf H, Mossner M, Nolte F, Jann JC, Nowak V, Zens B, Müdder K, Oblaender J et al. (2013). O-013 Mesenchymal stromal cells support significant engraftment of low-risk myelodysplastic syndromes (MDS) in a murine xenograft model. Leukemia Research. vol. 37,

Mossner M, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Schlenk R, Bug G et al. (2013). P-316 TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial. Leukemia Research. vol. 37,

Medyouf H, Nolte F, Mossner M, Nowak V, Zens B, Muedder K, Oblaender J, Fey S et al. (2013). Engraftment of Immature Hematopoietic Low Risk Myelodysplastic Syndrome (MDS) Cells in Conjunction with MSCs. ANNALS OF HEMATOLOGY. vol. 92, S59-S59.

Mossner M, Nolte F, Hütter G, Reins J, Klaumünzer M, Nowak V, Obländer J, Ackermann K et al.(2013). Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonalityll assay. Journal of Medical Genetics vol. 50, (2) 108-117.

Reinwald M, Haag A, Lengfelder E, Mossner M, Hanfstein B, Nowak V, Klaumuenzer M, Nolte F et al. (2012). Genome Wide DNA Methylation Analysis Identifies a Characteristic Methylation Profile for Patients with Acute Promyelocytic Leukemia and FLT3-Internal Tandem Duplication. Blood. vol. 120, 3521-3521.

Reinwald M, Nowak D, Platzbecker U, Giagounidis A, Go¿tze KS, Ottmann OG, Haase D, Shirneshan K et al. (2012). Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. Blood. vol. 120, 3801-3801.

Medyouf H, Nolte F, Mossner M, Nowak V, Zens B, Mu¿dder K, Obla¿nder J, Fey S et al. (2012). Significant Engraftment of Immature Hematopoietic Cells From Patients with Low Risk Myelodysplastic Syndromes (MDS) in Immunodeficient Mice. Blood. vol. 120, 1694-1694.

Schwaab J, Ernst T, Erben P, Rinke J, Schnittger S, Ströbel P, Metzgeroth G, Mossner M et al.(2012). Activating CBL mutations are associated with a distinct MDS/MPN phenotype. Annals of Hematology vol. 91, (11) 1713-1720.

Fabarius A, Giehl M, Mossner M, Nowak V, Schumann C, Nowak D, Haass W, Klein S et al. (2012). Centrosome aberrations as detected in patients with myelodysplastic syndromes correlate with chromosomal instability. ONKOLOGIE. vol. 35, 17-17.

Klaumuenzer M, Mossner M, Nowak V, Oblaender J, Fey S, Hanfstein B, Reinwald M, Nolte F et al. (2012). Functional analysis of EF413001 as a differentially regulated candidate gene in Acute Promyelocytic Leukemia (APL) and hematopoietic stem cells. ONKOLOGIE. vol. 35, 174-174.

Medyouf H, Nolte F, Mossner M, Nowak V, Zens B, Muedder K, Oblaender J, Fey S et al. (2012). CHARACTERIZATION OF MALIGNANT HEMATOPOIETIC STEM CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN A XENOGRAFT MODEL. EXPERIMENTAL HEMATOLOGY. vol. 40, S42-S43.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A et al.(2012). SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosomes and Cancer vol. 51, (8) 756-767.

Hopfer O, Nolte F, Mossner M, Komor M, Kmetsch A, Benslasfer O, Reißmann M, Nowak D et al.(2012). Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. European Journal of Haematology vol. 88, (2) 144-153.

Reinwald M, Haag A, Lengfelder E, Nowak V, Mossner M, Klaumuenzer M, Nolte F, Buechner T et al. (2011). Genome Wide DNA Methylation Analysis Reveals Significant Differences Between Blasts of Patients with Acute Promyelocytic Leukemia and CD34(+)-Hematopoietic Stem Cells of Healthy Individuals. BLOOD. vol. 118, 631-631.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A et al. (2011). Identification of Recurrent Submicroscopic Deletions of chromosomelq31.3 As Possible Molecular Prognostic Markers in Acute Promyelocytic Leukemia (APL). BLOOD. vol. 118, 193-194.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Jumaa H, Ye BH et al. (2011). Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. BLOOD. vol. 118, 613-613.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H et al.(2011). Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood vol. 118, (15) 4174-4178.

Philipp M, Schwaab J, Hanfstein B, Munjal U, Kalmanti L, Nowak D, Mossner M, Hofmann W-K et al. (2011). Changes in transketolase-like gene 1 expression in chronic myeloid leukemia. ONKOLOGIE. vol. 34, 267-268.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Hecht A et al. (2011). Comprehensive high density SNP array analysis of acute promyelocytic leukemia (APL) identifies multiple collateral genomic lesions and indicates recurrent micro-deletions of chromosome 1q31.3 as a new marker of unfavorable outcome. ONKOLOGIE. vol. 34, 105-106.

Hütter G, Kaiser M, Neumann M, Mossner M, Nowak D, Baldus CD, Gökbuget N, Hoelzer D et al.(2011). Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leukemia Research vol. 35, (5) 614-619.

Reins J, Mossner M, Richter L, Kmetsch A, Thiel E, Haase D, Hofmann WK(2011). Whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing. BioTechniques vol. 50, (3) 161-164.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Ogawa S et al. (2011). HIGH DENSITY SNP ARRAY ANALYSIS OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IDENTIFIES MULTIPLE COLLATERAL GENOMIC LESIONS AND INDICATES RECURRENT MICRODELETIONS OF CHROMOSOME 1q31.3 AS A NEW POSSIBLE INDICATOR OF UNFAVORABLE OUTCOME. ANNALS OF HEMATOLOGY. vol. 90, S24-S24.

Heesch S, Bartram I, Neumann M, Reins J, Mossner M, Schlee C, Stroux A, Haferlach T et al.(2011). Expression of IGFBP7 in acute leukemia is regulated by DNA methylation. Cancer Science vol. 102, (1) 253-259.

Reins J, Mossner M, Neumann M, Platzbecker U, Schumann C, Thiel E, Hofmann WK(2010). Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. Leukemia Research vol. 34, (12) 1610-1616.

Mossner M, Nowak D, Klaumu¿nzer M, Nowak V, Ackermann K, Brendel S, Obla¿nder J, Hopfer O et al. (2010). Detection of Highly Clonal CD34+, Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay. Blood. vol. 116, 977-977.

Nowak D, Klaumuenzer M, Hanfstein B, Mossner M, Nolte F, Nowak V, Oblaender J, Ogawa S et al. (2010). High Density SNP Array Analysis of Acute Promyelocytic-Leukemia (APL) Detects New Common Genomic Copy Number Alterations as Possible Cooperating Lesions. BLOOD. vol. 116, 1121-1122.

Nowak D, Ogawa S, Klaumuenzer M, Mossner M, Nolte F, Nowak V, Oblaender J, Erben P et al. (2010). High-density SNP array analysis of low risk MDS according to IPSS identifies submicroscopic genomic lesions targeting genes involved in epigenetic regulation. ONKOLOGIE. vol. 33, 222-222.

Nowak D, Mossner M, Klaumuenzer M, Nowak V, Nolte F, Hofmann WK (2010). Integrative methylation and gene expression analysis in CD34+bone marrow cells from patients with MDS and healthy donors with Infinium27 methylation arrays and HG-U133 plus 2 arrays. ONKOLOGIE. vol. 33, 222-223.

Heesch S, Bertram I, Neumann M, Reins J, Mossner M, Schlee C, Stroux A, Haferlach T et al. (2010). Methylation analysis and gene expression profiling of IGFBP7 reveal insights into its role in acute leukemia. ONKOLOGIE. vol. 33, 211-211.

Hopfer O, Benlasfer O, Mossner M, Nolte F, Thiel E, Hofmann W-K (2010). Survivin down regulation but no ubiquitary hypermethylation of its promotor during in vitro erythropoietic differentiation of MDS hematopoietic progenitor cells. ONKOLOGIE. vol. 33, 36-36.

Hofmann WK, Mossner M, Klaumuenzer M, Nowak V, Nolte F, Schumann C, Nowak D (2010). GENE EXPRESSION PROFILING AND INTEGRATIVE METHYLATION ANALYSIS IN CD34+BONE MARROW CELLS FROM PATIENTS WITH MDS AND HEALTHY DONORS WITH INFINIUM27 METHYLATION ARRAYS AND HG-U133 PLUS 2 ARRAYS. EXPERIMENTAL HEMATOLOGY. vol. 38, S74-S75.

Mossner M, Hopfer O, Nowak D, Baldus CD, Neumann U, Kmetsch A, Benlasfer O, John T et al.(2010). Detection of differential mitotic cell age in bone marrow CD34⁺ cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature. Experimental Hematology vol. 38, (8) 661-665.

Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS et al.(2010). SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood vol. 115, (5) 1049-1053.

Mossner M, Nowak D, Benlasfer O, Reins J, Hopfer OJ, Baldus CD, Thiel E, Hofmann W-K (2009). Identification of Highly Clonal Cells in CD34+and Unselected Bone Marrow Samples From Patients with Myelodysplastic Syndrome Using a Sensitive Quantitative PCR Approach. BLOOD. vol. 114, 699-699.

Nowak D, Kawamata N, Niebuhr B, Nowak V, Mossner M, Nahar RR, Thoennissen NH, Iwanski GB et al. (2009). The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. BLOOD. vol. 114, 526-527.

Reins J, Mossner M, Platzbecker U, Thiel E, Hofmann W-K (2009). Transcriptional Down-Regulation of the Wnt Antagonist SFRP1 Is Associated to Promoter Hypermethylation as Detected by Pyrosequencing in Hematopolietic Cells of Patients with Different Risk-Types of MDS, ALL and AML. BLOOD. vol. 114, 696-696.

Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S et al.(2009). Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica vol. 94, (10) 1383-1390.

Reins J, Mossner M, Kmetsch A, Platzbecker U, Thiel E, Hofmann WK (2009). ANALYSIS OF EXPRESSION OF THE WNT-ANTAGONIST SFRP1 AND QUANTIFICATION OF ITS PROMOTER METHYLATION BY PYROSEQUENCING IN BONE MARROW MONONUCLEAR CELLS FROM PATIENTS WITH DIFFERENT RISK-TYPES OF MDS, ALL, AND AML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 94, 321-322.

Bohne A, Schlee C, Mossner M, Thibaut J, Heesch S, Thiel E, Hofmann WK, Baldus CD(2009). Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leukemia Research vol. 33, (6) 817-822.

Hutter G, Nowak D, Mossner M, Ganepola S, Müß A, Allers K, Schneider T, Hofmann J et al.(2009). Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. New England Journal of Medicine vol. 360, (7) 692-698.

Nowak D, Nolte F, Mossner M, Nowak V, Baldus CD, Hopfer O, Noll S, Thiel E et al.(2009). Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. Experimental Hematology vol. 37, (2)

Mossner M, Hopfer O, Baldus CD, Neumann U, Kmetsch A, Benlasfer O, Thiel E, Hofmann W-K (2008). Detection of Differential Mitotic Cell Ages in Bone Marrow CD34+Cells Selected from Patients with Myelodysplastic Syndrome and Acute Leukemia by Pyrosequencing Analysis of An Epigenetic Molecular Clock DNA Signature. BLOOD. vol. 112, 931-931.

Hopfer OJ, Komor M, Freitag C, Mossner M, Hoelzer D, Thiel E, Hofmann W-K (2008). Epigenetic Dysregulation of GATA1 but Not Downstream Notch Effectors is Involved in MDS Dyserythropoiesis. BLOOD. vol. 112, 583-583.

Huetter G, Nowak D, Mossner M, Ganepola S, Allers K, Schneider T, Hofmann J, Hofmann WK et al. (2008). Treatment of HIV-1 infection by allogeneic CCR5-delta32 stem cell transplantation. BONE MARROW TRANSPLANTATION. vol. 41, S123-S123.

Nowak D, Wagner F, Nolte F, Baldus CC, Hopfer O, Mossner M, Serbent V, Thiel E et al. (2007). P069 Genome-wide DNA-mapping of CD34+ cells from MDS patients with 500K SNP arrays identifies significant regions of genomic alterations. Leukemia Research. vol. 31,

Nowak D, Wagner F, Baldus CC, Hopfer O, Mossner M, Serbent V, Thiel E, Hofmann WK (2006). Detailed Genome-Wide DNA-Mapping of CD34+ Cells Purified from Patients with MDS Using High-Resolution SNP Arrays Identifies Significant Regions of Genomic Alterations. Blood. vol. 108, 2635-2635.

Nowak D, Mossner M, Baldus CD, Hopfer O, Thiel E, Hofmann WK(2006). Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism. International Journal of Medical Sciences vol. 3, (4) 148-151.